Rheumatoid Arthritis (RA)
Non-Hodgkin’s Lymphoma (NHL)
RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
Chronic Lymphocytic Leukemia (CLL)
RIABNI™, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
RIABNI™, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
After you've made the decision to treat with RIABNITM, we’re here to help
Call 1-866-AMG-ASST
(1-866-264-2778)Monday to Friday,
9:00 am to 8:00 pm ET
*Co-pay support available for commercially eligible patients only; additional resources may be available for independent patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Amgen has no control over these programs and provides referrals as a courtesy only.
†Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen FIRST STEPTM Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost.
Obtain patient insurance coverage and cost information
Allows access specialist to provide case-specific support
Refer to this guide for billing and coding information as well as general information about how to use RIABNI™
Sample letter template that can be used to demonstrate medical necessity
Sample letter template that can be used if appealing a PA denial
Refer to this guide for billing and coding information as well as general information about how to use RIABNI™
Amgen has a sponsorship with National Infusion Center Association (NICA) to help your RIABNITM patients and your practice find alternative sites of care in your area
Simple educational content to help patients feel confident about receiving a biosimilar (based on FDA guidance)
Your patient's guide to understanding and starting treatment with RIABNITM
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.
RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
RIABNI™ is a trademark of Amgen, Inc.
Rituxan® is a registered trademark of Biogen.
Truxima® is a registered trademark of Teva Pharmaceuticals.
Ruxience® is a trademark of Pfizer.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.
RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
RIABNI™ is a trademark of Amgen, Inc.
Rituxan® is a registered trademark of Biogen.
Truxima® is a registered trademark of Teva Pharmaceuticals.
Ruxience™ is a trademark of Pfizer.